Latest News
-

HDBuzz Is Officially Independent: What This Means, and Why It Matters
We’re entering a new chapter. HDBuzz is now an independent organisation, strengthening our ability to report clearly, critically, and responsibly on HD research.
-

Chubby mice reveal the importance of the hypothalamus in Huntington's disease
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-

The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-

Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-

FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-

Successful gene therapy trial in Parkinson’s Disease gives hope for HD
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-

Gene silencing for HD: the story so far
Is gene silencing as exciting as it sounds for HD, and what might the future hold?
-

Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis
HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc
-

What do sheep brains have to do with HD?
How smart are sheep, and why do HD researchers care?
-

Interview: CHDI Management
HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide
-

CHDI Report: Day 3
Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
Previously featured
-
HDBuzz Is Officially Independent: What This Means, and Why It Matters
-
2025: Year in Review
-
Break Up With Your CAGs: How Three Letters Could Change Huntington’s Disease
-
First participants dosed in new POINT-HD huntingtin-lowering trial
-
A road less traveled: how making less huntingtin can alter somatic instability and may delay symptoms
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
